Comparative Pharmacology
Head-to-head clinical analysis: EYSUVIS versus INFLAMASE MILD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EYSUVIS versus INFLAMASE MILD.
EYSUVIS vs INFLAMASE MILD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Eysuvis (loteprednol etabonate ophthalmic suspension) is a corticosteroid that works by inducing phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid and subsequent synthesis of prostaglandins and leukotrienes, thereby reducing inflammation.
Inflammase Mild is a combination product containing hydrocortisone, a corticosteroid that acts by inducing phospholipase A2 inhibitory proteins, thereby inhibiting the release of arachidonic acid and reducing prostaglandin and leukotriene synthesis. It also contains benzalkonium chloride, a quaternary ammonium compound with antiseptic properties.
1 drop in each eye twice daily (approximately 12 hours apart) for 4 weeks.
N/A
None Documented
None Documented
Approximately 2-4 hours for loteprednol etabonate; clinical effect correlates with dosing interval (e.g., 4 times daily).
1.5-2.5 hours; short half-life allows frequent dosing for mild inflammation.
Primarily renal (90-95% as unchanged drug and metabolites); minor biliary/fecal (<5%).
Renal excretion of unchanged drug (approximately 60%) and glucuronide conjugate (20%); biliary/fecal (15%).
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid